Mikko K.
- Country
- Finland
- Department
- Comprehensive Cancer Center, Department of Hematology
Research Overview
- Phase 3 Randomized Trial of Bortezomib, Lenalidomide, Dexamethasone, and Ciltacabtagene Autoleucel in Newly Diagnosed Multiple Myeloma Without Planned Stem Cell Transplant
- Phase 3 Randomized Study of BMS-986393 CAR-T Therapy Versus Standard Regimens in Relapsed/Refractory Lenalidomide-Refractory Multiple Myeloma
Data & Insights
Has run more than one trial at 27 of 97 partner sites.
Specializations
Multiple Myeloma Treatment
The investigator specializes in developing innovative therapeutic approaches for multiple myeloma, with particular emphasis on CAR T-cell therapy applications in both newly diagnosed and refractory cases.
- Novel Combination Therapies
- CAR T-cell Development
- Treatment Resistance Management
Their research encompasses both standard therapeutic combinations and emerging cellular therapies.
Hematologic Innovations
The investigator focuses on advancing targeted immunotherapy approaches, particularly exploring GPRC5D-directed treatments and various therapeutic combinations for blood cancers.
- Immunotherapy Development
- Treatment Sequencing
- Drug Resistance Solutions
Their work integrates novel therapeutic agents with established treatment protocols.
Treatment Optimization
The investigator's work centers on optimizing therapeutic strategies for patients ineligible for stem cell transplantation and those with refractory disease.
- Alternative Treatment Pathways
- Maintenance Therapy Approaches
- Progressive Disease Management
Their research addresses critical treatment gaps in challenging patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.